India Biologics Market Size and Trends for 2026

The India biologics market size is projected to grow from USD 14.56 billion by 2025, surpassing USD 15.99 billion in 2026 to reach USD 37.08 billion by 2035, at a CAGR of 9.80% during the forecast period from 2026 to 2035.

Key Highlights

• North America held a major revenue share of the market by 55% in 2025.
• Asia-Pacific is expected to host the fastest-growing market by 9.40% CAGR in the coming years.
• By disease category, the oncology segment dominated the market in 2025.
• By disease category, the hematological disorder segment is expected to expand rapidly in the market in the coming years.
• By source, the microbial segment held the led the market in 2025.
• By source, the mammalian expression systems segment is expected to witness significant growth in the market over the forecast period.
• By manufacturing, the in-house segment accounted for the highest revenue share of the market in 2025.
• By manufacturing, the outsourcing segment is expected to grow with the highest CAGR in the market during the studied years.
• By product, the monoclonal antibodies segment held a dominant revenue share of the market in 2025.
• By product, the antisense and RNAi therapeutics segment is expected to grow at the fastest CAGR in the market during the forecast period.

Biologics Market Overview

"The American Cancer Society estimates 1.92 million new cancer cases and 609,360 deaths in the U.S., contributing to a global toll of 9.6 million lives lost in 2022. Biologics, monoclonal antibodies, and immunotherapies revolutionize cancer care, boosting survival and minimizing side effects."

Biologics are therapeutic products derived from living organisms or their components, such as cells, proteins, or nucleic acids. Unlike traditional drugs, which are often chemically synthesized, biologics are typically large and complex molecules produced using advanced technologies like genetic engineering. This complexity allows them to closely mimic the natural substances in the human body, making them more targeted and specific in their actions. One significant aspect of biologics is their role in treating diseases at the molecular and cellular levels. They are designed to interact with specific biological pathways and mechanisms, making them highly effective in addressing the underlying causes of various diseases. This targeted approach can result in better treatment outcomes and, in many cases, fewer adverse effects than conventional drugs.

The application of biologics spans a wide range of therapeutic areas. One prominent example is their use in oncology. Monoclonal antibodies, a biologic, have revolutionized cancer treatment by selectively targeting cancer cells while sparing healthy cells. This targeted action helps minimize damage to surrounding tissues and reduces side effects commonly associated with traditional chemotherapy. In autoimmune disorders, where the immune system mistakenly attacks the body's tissues, biologics can modulate specific immune response components. This helps to restore the balance and alleviate symptoms without suppressing the entire immune system, as is often the case with conventional treatments.

The growth of the biologics market is fueled by ongoing advancements in biotechnology, such as improved techniques for protein engineering and manufacturing processes. These innovations enable the development of novel and more sophisticated biological therapies. It's important to note that biologics often come with higher production costs and can be more challenging to manufacture than small-molecule drugs. This can result in higher prices for biological treatments. Despite this, the demand for biologics continues to rise due to their ability to provide effective and often life-changing solutions for patients facing various health challenges.

Additionally, the biologics market represents a transformative shift in medicine, offering targeted and personalized treatments that leverage the body's natural processes to address diseases at their roots. As research and development in biotechnology advance, we can expect further innovations and an expanding role for biologics in improving healthcare outcomes across diverse therapeutic areas.

Biologics Market Companies

• Amgen
• Merck & Co.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb
• Sanofi
• Bayer AG
• AstraZeneca
• GlaxoSmithKline Plc.
• Novartis AG
• Eli Lilly and Company

Biologics Market Segments

By Source

• Microbial
• Mammalian
• Others

By Product

• Monoclonal Antibodies
  • By Application
    • Diagnostic
      • Biochemical Analysis
      • Diagnostic Imaging
    • Therapeutic
      • Direct mAb Agents
      • Targeting mAb Agents
    • Protein Purification
    • Others
  • By Type
    • Murine
    • Chimeric
    • Humanized
    • Human
    • Others
• Antisense & RNAi Therapeutics
• Vaccines
• Recombinant Proteins
• Others

By Disease Category

• Oncology
• Hematological Disorders
• Infectious Disorders
• Immunological Disorders
• Cardiovascular Disorders
• Others

By Manufacturing

• In-house
• Outsourcing